No Data
Enwei Pharmaceuticals: Report for the third quarter of 2024
Enwei Pharmaceutical (301331.SZ) released its performance for the first three quarters, with a net income of 22.02 million yuan, a year-on-year decrease of 69.81%.
Enwei Medicine (301331.SZ) disclosed the third quarter report of 2024, achieving revenue of 5....
Enwei Pharmaceutical (301331.SZ): has repurchased 3.03% of the shares accumulated.
On October 9th, Gelonhui: Enwei Pharmaceuticals (301331.SZ) announced that as of September 30, 2024, the company has repurchased a total of 3,113,313 shares through a repurchase dedicated securities account in a centralized auction trading manner, accounting for 3.0258% of the total number of company shares (calculated based on the total share capital of the company as of September 30, 2024 of 102,891,887 shares), with the highest fill price at 44.78 yuan per share, the lowest fill price at 21.31 yuan per share, and a total transaction amount of 101,713,739.41 yuan (excluding transaction costs).
Enwei Medicine (301331.SZ): The core product "Jie Er Yin Cleansing Solution" has ranked first in the sub-category of "inflammation" in the field of chinese patent medicine in gynecology in urban retail pharmacies in China for multiple consecutive years.
Gelonghui September 24th | Enwei Medicine (301331.SZ) stated at an investor relations event that the company's core product, 'Jieeryin Cleansing Liquid,' not only has ranked first in the 'inflammation sub-category' market share in the field of chinese patent medicine in urban retail pharmacies in China for many years, but also made its debut at the top of the 'Urban Physical Pharmacy Terminal Gynecological Chinese Patent Medicine Brand List' in the first half of 2023. The company got involved in branded products early and developed products like 'Herbal Antimicrobial Cleansing Liquid,' 'Feminine Care Liquid,' and other products, which have been well received in the market due to their excellent product quality. In addition, focusing on women's health care, leveraging the Jieeryin brand, the company has also developed foams.
Enwei Pharmaceuticals: 2024 Semi-Annual Report
Enwei Pharmaceuticals: 2024 Semi-Annual Report Summary
No Data
No Data